D-1064-2016 Class II Terminated
FDA drug recall D-1064-2016 was initiated by Allergan Sales, LLC on May 10, 2016 and is designated Class II. Reason for recall: Failed Content Uniformity Specifications. The recall status is terminated (terminated Dec 6, 2017). Affected quantity: 17802 units.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 13, 2016
- Initiation Date
- May 10, 2016
- Termination Date
- Dec 6, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 17802 units
Product description
Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan Inc, Irvine, CA 92612
Reason for recall
Failed Content Uniformity Specifications.
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot #: a) 84172, b) 84173, Exp FEB/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1064-2016
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026